INTRODUCTION: We investigated potential relationships of history of diabetes mellitus (DM) and glycemic control, represented by hemoglobin A1c (HbA1c) level, with characteristics of tumor among patients who received radical prostatectomy (RP) for clinically localized prostate cancer. METHODS: We reviewed data of 740 patients who underwent RP for clinically localized prostate cancer between 2004 and 2008 without receiving preoperative radiation or hormonal treatment. Univariate and multivariate logistic regression analyses addressed the associations of history of DM and HbA1c level with known prognostic variables of prostate cancer. RESULTS: No significant differences were observed in various preoperative and pathological parameters between those with (n = 89) and without DM (n = 651). When only the subjects with DM were divided into two groups (group 1 and 2) according to HbA1c level (<6.5% vs. >/=6.5%), group 2 demonstrated significantly higher rate of extraprostatic extension of tumor (P = 0.043) and high (>/=7) pathological Gleason score (P = 0.005) than group 1. Also among those with DM, HbA1c level was observed to be an independent predictor for high pathologic Gleason score (P = 0.010) and extraprostatic extension of tumor (P = 0.035), respectively in multivariate analyses. CONCLUSION: Although simple history of having DM may not be a significant factor regarding aggressiveness of clinically localized prostate cancer, the glycemic control, as represented by HbA1c level, may be a useful preoperative predictor of aggressive tumor profile among patients with DM who are also diagnosed with clinically localized prostate cancer. (c) 2009 Wiley-Liss, Inc.
INTRODUCTION: We investigated potential relationships of history of diabetes mellitus (DM) and glycemic control, represented by hemoglobin A1c (HbA1c) level, with characteristics of tumor among patients who received radical prostatectomy (RP) for clinically localized prostate cancer. METHODS: We reviewed data of 740 patients who underwent RP for clinically localized prostate cancer between 2004 and 2008 without receiving preoperative radiation or hormonal treatment. Univariate and multivariate logistic regression analyses addressed the associations of history of DM and HbA1c level with known prognostic variables of prostate cancer. RESULTS: No significant differences were observed in various preoperative and pathological parameters between those with (n = 89) and without DM (n = 651). When only the subjects with DM were divided into two groups (group 1 and 2) according to HbA1c level (<6.5% vs. >/=6.5%), group 2 demonstrated significantly higher rate of extraprostatic extension of tumor (P = 0.043) and high (>/=7) pathological Gleason score (P = 0.005) than group 1. Also among those with DM, HbA1c level was observed to be an independent predictor for high pathologic Gleason score (P = 0.010) and extraprostatic extension of tumor (P = 0.035), respectively in multivariate analyses. CONCLUSION: Although simple history of having DM may not be a significant factor regarding aggressiveness of clinically localized prostate cancer, the glycemic control, as represented by HbA1c level, may be a useful preoperative predictor of aggressive tumor profile among patients with DM who are also diagnosed with clinically localized prostate cancer. (c) 2009 Wiley-Liss, Inc.
Authors: Howard S Kim; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Prostate Date: 2010-10-01 Impact factor: 4.104
Authors: Farnoosh Nik-Ahd; Lauren E Howard; Adva T Eisenberg; William J Aronson; Martha K Terris; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Stephen J Freedland Journal: Cancer Date: 2019-04-29 Impact factor: 6.860
Authors: Jeannette M Schenk; Marian L Neuhouser; Sarah J Beatty; Matthew VanDoren; Daniel W Lin; Michael Porter; John L Gore; Roman Gulati; Stephen R Plymate; Jonathan L Wright Journal: Contemp Clin Trials Date: 2019-04-16 Impact factor: 2.226
Authors: J L Wright; S R Plymate; M P Porter; J L Gore; D W Lin; E Hu; S B Zeliadt Journal: Prostate Cancer Prostatic Dis Date: 2013-03-05 Impact factor: 5.554
Authors: Jeffrey Shevach; Emily Jane Gallagher; Teena Kochukoshy; Victoria Gresia; Manpreet Brar; Matthew D Galsky; William K Oh Journal: Front Oncol Date: 2015-06-15 Impact factor: 6.244